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Abstracts
ficacy data was obtained from two randomised clinical tri-
als comparing Pip-Taz (4g/0.5g t.i.d.) with Imi-Cil (hig
level dose, 19/1g t.i.d.; low level dose, 0.5g/0.5g t.i.d., re-
spectively). Information on treatment patterns and re-
sources used was obtained from five physicians in Spain
with experience in treating this condition. Prices or unit
costs were obtained from a wide range of sources including
published articles and government publications. All prices
are presented in 1995 local currency (Pts). The robustness
of the results was tested using a sensitivity analysis.
RESULTS: The efficacy rate (obtained from the analysis
of intention-to-treat patients with clinical success) of Pip-
Taz was higher (+12.5%) than low-level doses and equal
(+4.0%) to high-level doses of Imi-Cil. The incremental
costs in the Pip-Taz group were -81,651 Pts (average
cost: 543,12 Pts vs. 624,773 Pts) and -33,217 Pts
(487,698 Pts vs, 520,915 Pts) in comparison with high-
and low-level doses of Imi-Cil, respectively. According to
the incremental cost-effectiveness analysis, the Pip-Taw
treatment would result in a saving per every additional
patient with clinical success of 2,041,275 Pts and
265,736 Pts versus high and low doses of Imi-Cil, respec-
tively. However, in the hypothetical case that the Imi-
Cil's clinical efficacy was higher than the Pip-Taz effi-
cacy, the former treatment would provide savings.
CONCLUSIONS: This model shows that Pip-Taz clinical
efficacy is higher or equal to Imi-Cil, and in that case,
Pip-Taw would prove to be more cost-effective than Imi-
Cil in the treatment of intra-abdominal infections.
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HOSPITAL LENGTH OF STAY FOR COMMUNITY-
ACQUIRED PNEUMONIA PATIENTS
Tan H, Koeller J
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OBJECTIVE: To assess variations in hospital length of
stay for community-acquired pneumonia patients, adjusted
for severity of illness using a pneumonia-specific model as
described by Fine et al. in the N Engl J Med 1997;336:
243-50.
METHODS: All patients admitted to University Hospi-
tal, San Antonio, during January-December 1996 with a
primary ICD-9CM diagnosis of 486 (pneumonia with no
organism specified) were evaluated retrospectively via
chart review. Patient demographics data, clinical find-
ings, hospital resource utilization such as length of stay,
length of antibiotic therapy, and hospital mortality were
collected. Patients were stratified into five risk classes.
RESULTS: A total of 187 patients was evaluated. There
were (36, 60, 42, 40, 9) patients in risk classes (I, II, III,
IV, V) . Hospital length of stay for patients in classes (I,
II, III, IV, V) were in order LOS£3 days (5, 13, 12, 3, 2),
LOS 4-7 days (24, 39, 20,18,1), and LOS >7 days (7, 8,
10, 19, 6), respectively. Average length of hospital stay
69
was (6.6, 5.1, 6.2, 8.1, 9.6) days in classes I-V, respec-
tively, Anova P < 0.0026.
CONCLUSION: Variations exist in hospital LOS among
the five groups. 81% (78 patients in I and II combined)
were treated >3 days, and 71 % (30 patients in class III)
were treated >3 days. These low to moderate risk classes
(I, II, III) could be a target for reduced LOS, quality assur-
ance, and cost-effectiveness program. These differences in
LOS could be attributed to other unmeasured patient, phy-
sician, or hospital related factor and its process of care.
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Epoetin alpha (Epo) for use in dialysis patients represents
a substantial expenditure for academic medical centers.
OBJECTIVE: The purpose of this study was to evaluate
the efficiency and accuracy of Epo billing and reimburse-
ment systems administered and dispensed in 8 geographi-
cally distributed academic health centers.
METHODS: A retrospective chart review was performed
for 604 patients across the 8 centers, during the third or
fourth quarter of 1989 or the third quarter of years 1990
through 1993. Data collected included HCFA provider
number, Medicare number, quantity of Epo prescribed,
quantity of Epo recorded as administered for home dialy-
sis, number of doses of Epo not administered as pre-
scribed, reason for missing dose, available hemoglobin and
hematocrit values, and relevant information to explain
skipped dialysis treatments. The number of units adminis-
tered or dispensed for home use was matched to an ab-
stract of the HCFA reimbursement files for comparison.
RESULTS: Approximately 18 % of the total Epo actually
administered and/or dispensed during the course of the
study was not represented in the HCFA reimbursement
data. This ranged from 2% to 45% in the different cen-
ters. The total volume of Epo administered or dispensed
per center was not related to the percentage of under-
representation in the HCFA reimbursement files.
CONCLUSION: Epo administered and/or dispensed to
Medicare primary dialysis outpatients was under-repre-
sented in HCFA reimbursement data. As a result, institu-
tions may be experiencing a significant loss of reimburse-
ment. The exact reasons for this discrepancy are unclear.
Institutions should evaluate their Epo reporting/billing
policies and procedures to potentially increase revenue re-
covery they are due.
